首页> 外文期刊>Drug development and industrial pharmacy >Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
【24h】

Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.

机译:质子泵抑制剂口服固体剂型的延迟释放薄膜包衣应用:案例研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Formulation of proton pump inhibitors (PPIs) into oral solid dosage forms is challenging because the drug molecules are acid-labile. The aim of this study is to evaluate different formulation strategies (monolithic and multiparticulates) for three PPI drugs, that is, rabeprazole sodium, lansoprazole, and esomeprazole magnesium, using delayed release film coating applications. METHOD: The core tablets of rabeprazole sodium were prepared using organic wet granulation method. Multiparticulates of lansoprazole and esomeprazole magnesium were prepared through drug layering of sugar spheres, using powder layering and suspension layering methods, respectively. Tablets and drug-layered multiparticulates were seal-coated, followed by delayed release film coating application, using Acryl-EZE(R), aqueous acrylic enteric system. Multiparticulates were then filled into capsules. The final dosage forms were evaluated for physical properties, as well as in vitro dissolution testing in both compendial acid phase, 0.1N HCl (pH 1.2), and intermediate pH, acetate buffer (pH 4.5), followed by phosphate buffer, pH 6.8. The stability of the delayed release dosage forms was evaluated upon storage in accelerated conditions [40 degrees C/75% relative humidity] for 3 months. RESULTS: All dosage forms demonstrated excellent enteric protection in the acid phase, followed by rapid release in their respective buffer media. Moreover, the delayed release dosage forms remained stable under accelerated stability conditions for 3 months. CONCLUSIONS: Results showed that Acryl-EZE enteric coating systems provide excellent performance in both media (0.1N HCl and acetate buffer pH 4.5) for monolithic and multiparticulate dosage forms.
机译:背景:将质子泵抑制剂(PPI)配制成口服固体剂型具有挑战性,因为药物分子对酸不稳定。这项研究的目的是使用延迟释放薄膜包衣应用评估三种PPI药物(雷贝拉唑钠,兰索拉唑和埃索美拉唑镁)的不同制剂策略(整体和多颗粒)。方法:采用有机湿法制粒制备雷贝拉唑钠片。兰索拉唑和埃索美拉唑镁的多颗粒分别通过粉末球和悬浮液分层法通过糖球的药物分层制备。使用Acryl-EZE水性丙烯酸肠溶体系将片剂和药物层状多颗粒密封包衣,然后延迟释放膜包衣。然后将多颗粒填充到胶囊中。评估了最终剂型的物理性质,以及在链状酸性相0.1N HCl(pH 1.2)和中间pH,乙酸盐缓冲液(pH 4.5)和磷酸盐缓冲液(pH 6.8)中的体外溶出度测试。在加速条件[40℃/ 75%相对湿度]下储存3个月后,评估了延迟释放剂型的稳定性。结果:所有剂型在酸性阶段均表现出出色的肠溶保护作用,随后在各自的缓冲液中快速释放。此外,延迟释放剂型在加速稳定性条件下保持稳定3个月。结论:结果表明,对于单片和多颗粒剂型,Acryl-EZE肠溶衣系统在两种介质(0.1N HCl和乙酸盐缓冲液pH 4.5)中均具有出色的性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号